Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Want to see NTLA full AI Analyst Report?
NTLA Stock Chart & Stats
$14.95
-$0.56(-4.53%)
At close: 4:00 PM EST
$14.95
-$0.56(-4.53%)
Day’s Range― - ―
52-Week Range$6.83 - $28.25
Previous CloseN/A
Volume723.92K
Average Volume (3M)3.05M
Market Cap
$1.64B
Enterprise Value$1.51B
Total Cash (Recent Filing)$449.88M
Total Debt (Recent Filing)$93.33M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.83
Shares Outstanding118,133,545
10 Day Avg. Volume2,624,028
30 Day Avg. Volume3,050,344
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue22.32
Enterprise Value/Gross Profit-87.33
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$22.67Price Target Upside51.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)-3.56
Revenue Forecast (FY)$58.71M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Biomarker ResponseClinical data showing stabilization in walking distance paired with robust suppression of the disease biomarker suggests nex-z may deliver meaningful functional benefits for patients with advanced symptoms.
Commercial Demand And Program MomentumStronger-than-expected enrollment in the HAE study and high physician interest in the gene-editing portfolio support growing commercial demand for one‑time therapies and strengthen the case for nex-z's market potential.
Regulatory ClearanceFDA removal of the clinical hold on the MAGNITUDE ATTR-CM trial allows enrollment to resume and removes a major regulatory overhang for nex-z's development program.
Bears Say
Capital Needs And Potential DilutionUpsizing of the at‑the‑market equity offering to raise additional capital signals funding needs that could lead to future equity dilution and weigh on the stock.
Pricing And Payer ResistanceHigh upfront pricing typical of irreversible, one‑time therapies may face payer resistance, creating a meaningful commercial barrier to broad uptake of nex-z.
Safety Concerns From Liver InjuryA patient treated with nex-z met criteria for severe liver injury and subsequently died, raising significant safety concerns that could constrain adoption and invite stricter regulatory scrutiny.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $6.83 and its highest was $28.25 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.64B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 92 days.
How were Intellia Therapeutics’s earnings last quarter?
Currently, no data Available
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 118,133,545 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.67 (51.62% Upside)
$22.67 (51.62% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 813.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.77%
12-Months-Change
Fundamentals
Return on Equity
-56.63%
Trailing 12-Months
Asset Growth
-29.29%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
NTLA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$22.67
▲(51.62% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Ownership Overview
1.80% Insiders
18.18% Mutual Funds
2.99% Other Institutional Investors
47.32% Public Companies and Individual Investors